Skip to main content
Fig. 7 | Journal of Hematology & Oncology

Fig. 7

From: MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells

Fig. 7

Anti-tumor activity of mCART against LUAD was explored by LDH release assay in vitro. a The tumor-inhibitory rate of mCART in the H1299 and PC9 (both MAGE-A1 positive) cell lines was progressively upregulated along with the increase in the E:T ratio of mCART. The 20:1 ratio of mCART showed the most effective cell killing activity. In comparison, mCART was barely able to kill MAGE-A1-negative cell lines (HBE and PC (shMAGE)). *Significant difference in tumor-inhibitory rate in the mCART group compared with the T group. b A fixed 10:1 E:T ratio of mCART also demonstrated significant tumor-inhibitory efficacy in all MAGE-A1-positive LUAD cell lines. For all the cell viability assays, unrelated-CART and T showed no cell-killing activities, regardless of the E:T ratio selected or the cell type used.*Significant difference in tumor-inhibitory rate in the mCART group compared with the T group. c and d IFN-γ and IL-2 expression were detected when mCART was co-incubated with LUAD cells. The 10:1 E:T ratio of mCART was co-cultured with four different cell lines. After culturing, a larger amount of IFN-γ and IL-2 was released by mCART, and their release was highly associated with the level of MAGE-A1 expression in the LUAD cells. In contrast, the release of IFN-γ and IL-2 remained unchanged in unrelated-CART and T cells. *Significant difference in IFN-γ and IL-2 expression in the mCART group compared with the T group

Back to article page